id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-3341-0009,FDA,FDA-2016-E-3341,"Letter from Wenderoth, Lind & Ponack, LLP",Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T17:06:45Z,,0,0,09000064839c0233
FDA-2016-E-3341-0008,FDA,FDA-2016-E-3341,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-09-19T04:00:00Z,2018,9,2018-09-19T04:00:00Z,,2018-09-19T19:30:47Z,,0,0,0900006483727bda
FDA-2016-E-3341-0007,FDA,FDA-2016-E-3341,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-09-11T04:00:00Z,2018,9,2018-09-11T04:00:00Z,,2018-09-11T20:31:52Z,,0,0,09000064836dcd43
FDA-2016-E-3341-0006,FDA,FDA-2016-E-3341,Letter from RaQualia Pharma Inc.,Other,Letter(s),2018-03-19T04:00:00Z,2018,3,2018-03-19T04:00:00Z,,2018-03-19T15:28:01Z,,0,0,09000064830002d1
FDA-2016-E-3341-0005,FDA,FDA-2016-E-3341,"Determination of Regulatory Review Period for Purposes of Patent
Extension; ENTYCE",Notice,Determinations,2018-01-11T05:00:00Z,2018,1,2018-01-11T05:00:00Z,2018-03-13T03:59:59Z,2024-02-29T05:19:23Z,2018-00358,0,0,0900006482ddaca6